Fractyl Health reports Q3 net loss of $45.6 million on $77.7 million cash position
Reuters
Nov 13
<a href="https://laohu8.com/S/GUTS">Fractyl Health</a> reports Q3 net loss of $45.6 million on $77.7 million cash position
Fractyl Health Inc. reported a net loss of $45.6 million for the third quarter ended September 30, 2025, compared to a net loss of $23.2 million for the same period in 2024. The increase was primarily due to a $23.5 million non-cash accounting change in fair value related to warrants. Research and development expenses decreased to $17.5 million from $19.0 million in the prior year, mainly due to lower spending on the REVITALIZE-1 study and reduced stock-based compensation. Selling, general and administrative expenses were $5.2 million, up from $4.8 million, driven by costs associated with warrant issuance in August 2025. As of September 30, 2025, the company had $77.7 million in cash and cash equivalents and expects its cash position to fund operations into early 2027. During the quarter, Fractyl expanded its Board of Directors and reported progress in its Revita clinical programs, with several key data readouts and a potential PMA filing anticipated in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574374-en) on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.